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Abstract 
Four commercially available Factor Xa (FXa) reagents were evaluated in a fluorogenic anti-FXa assay. 
The four reagents - of which three were of human origin and the fourth was bovine - were compared in 
terms of the resulting assay dynamic ranges, lag times, CV and R
2
 values, sum of squares as well as their 
sensitivity to unfractionated heparin (UFH) within the therapeutic range of 0-1.2 U mL
-1
. Based on a 
balance of performance characteristics, an optimum reagent was selected which had the best combination 
of all parameters. The best performing serine endopeptidase in the fluorogenic anti-FXa assay was found 
to be bovine in nature and in liquid form. The resulting assay was very sensitive within the dynamic range 
of 0-1.2 U mL
-1
 showing a linear semi-logarithmic dose-response calibration curve with an R
2
 of 0.99 and 
CVs <7 %. Of the three human FXa evaluated, the lyophilised human FXa in the absence of stabilizers 
was demonstrated to be the best performing human FXa reagent. It showed similar behaviour to the 
bovine reagent in terms of lag time values and dynamic range but with reduced sensitivity. CVs and R
2
 
values were ≤ 2 % and 0.95, respectively, when considering all points in the linear regression fit.     
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Introduction 
Anticoagulant monitoring is necessary as overmedication using drugs such as warfarin or heparins may 
lead to excessive uncontrolled bleeding, while under dosage of these drugs can hamper their function in 
the prevention of thrombus formation [1]. Unfractionated heparin (UFH) is a widely utilized parenteral 
anticoagulant drug which functions to bind to the naturally occurring anticoagulant protein antithrombin 
(AT) to catalyse AT inhibition of thrombin and Factor Xa (FXa) in addition to other serine 
endopeptidases [2].   
Current methods of anticoagulant monitoring focus on clot-based assays. These assays, including the 
activated partial thromboplastin time (APTT) and activated clotting time (ACT), have several 
disadvantages [3,4] but continue to be used despite the fact that they lack standardization due to different 
reagents and instrumentation available for performing the wide range of commercially available tests 
[5,6]. In addition, the APTT and ACT can be affected by a number of coagulopathies (i.e. deficiencies of 
certain coagulation factors) [7].  
Alternative anticoagulant monitoring tests include anti-FXa assays which are sensitive to UFH. The most 
commonly used are chromogenic anti-FXa assays which are based on a colorimetric end-point 
measurement. Unfortunately, there are also some drawbacks to chromogenic anti-FXa assays such as the 
cost, lack of assay uniformity and limited published information on their use [8-10]. Moreover, these 
assays measure the change in absorbance of the sample, which complicates measurements in whole blood 
or platelet-rich-plasma (PRP) samples [11]. Therefore, consideration has been given to the development 
of fluorogenic anti-FXa assays, as these could allow for monitoring all forms of heparins in a range of 
sample types [3]. The principle behind the fluorogenic anti-FXa assay previously developed is that UFH, 
endogenous AT and FXa (added in excess) form a complex. The remaining FXa is free to cleave the 
fluorogenic substrate at a specific site, thus releasing the corresponding fluorophore which is inversely 
proportional to the concentration of UFH present in the sample.  
The purpose of this study was to compare the performance of four different commercially available FXa 
preparations in a previously-developed fluorogenic anti-FXa assay, and assess them in terms of resulting 
assay dynamic ranges, lag times, CV and R
2
 values, sum of squares as well as their sensitivity to UFH 
within the therapeutic range of 0-1.2 U mL
-1
. 
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Materials and methods 
Water (molecular biology reagent) and HEPES (minimum 99.5% titration) were purchased from Sigma-
Aldrich (Dublin, Ireland). Filtered HEPES was prepared at a concentration of 10 mM (pH 7.4). A 100 
mM filtered stock solution of CaCl2 from Fluka BioChemika (Buchs, Switzerland) was prepared from a 1 
M CaCl2 solution. 
Purified human/bovine FXa serine endopeptidase (code number: EC 3.4.21.6) was purchased from four 
different companies in lyophilized or liquid form, aliquoted into 10 L and stored at -20 °C until further 
use. The four FXa reagents used were as follows: Human FXa from Hyphen Biomed (Neuville-Sur-Oise, 
France) in lyophilized form was reconstituted in 500 μL water to give a final concentration of 4400 nM; 
Human FXa from Enzyme Research Laboratories Ltd. (Indiana, USA) in lyophilized form was 
reconstituted in 584 μL water to give a final concentration of 51 M; Bovine FXa from Sigma-Aldrich 
(Steinheim, Germany) was received in liquid form at a concentration of 117.4 M; Human FXa from 
Haematologic Technologies Inc. (Vermont, USA) was received in liquid form at a concentration of 206.5 
M. Table 1 summarises the characteristics of the four FXa preparations studied.  Stocks were 
subsequently used to prepare a working concentration of 12 nM FXa in 10 mM HEPES buffer for use in 
the fluorogenic anti-FXa assay.  
The fluorogenic substrate methylsulfonyl-D-cyclohexylalanyl-glycyl-arginine-7-amino-4-
methylcoumarin acetate (Pefafluor FXa) was purchased from Pentapharm (Basel, Switzerland). It was 
reconstituted in 1 mL of water having a final concentration of 10 mM, aliquoted and stored at -20 °C. 
Dilutions from 10 mM stock solutions down to 10 µM were freshly prepared with water when needed. 
Subsequent dilutions to 2.7 µM were prepared in 10 mM HEPES. Tubes were covered with aluminium 
foil to protect from exposure to light. 
Human pooled plasma was purchased from Helena Biosciences Europe (Tyne and Wear, UK). Plasma 
was received in lyophilized form. It was reconstituted in 1 mL water and left to stabilize for a minimum 
of 20 min at room temperature before use. UFH obtained from bovine lung tissue was acquired from 
Sigma-Aldrich (St Louis, MO). A stock solution of 100 U mL
-1
 was used to prepare all subsequent 
dilutions within the therapeutic range of 0–1.2 U mL-1. 
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(Table 1) 
 
Fluorescence intensities were measured on an Infinite M200 microplate reader from Tecan Group Ltd. 
(Männedorf, Switzerland) equipped with a UV Xenon flashlamp. Assays were performed in flat, black-
bottom 96-well polystyrol FluorNunc™ microplates from Thermo Fisher Scientific (Roskilde, Denmark). 
 
The experimental protocol previously developed by Harris et al. [3] was used. Briefly, to establish 
optimal assay concentrations, Pefafluor FXa fluorogenic substrate and FXa from Hyphen Biomed were 
titrated over a range of concentrations. The optimized fluorogenic anti-FXa assay consisted of 4 nM FXa. 
A stock solution of 12 nM FXa in 10 mM HEPES was prepared in each case. Stocks were then 
incorporated into the fluorogenic assay with freshly prepared fluorogenic substrate as indicated above. 
The reactions were carried out using UFH concentrations from 0 to 1.2 U mL
-1
 every 0.2 U mL
-1
 in 
human pooled plasma. The excitation/emission pair of 342/440 nm was used to monitor the formation of 
the fluorophore 7-amino-4-methylcoumarin (AMC). The reaction rate (slope), which was defined as the 
change in fluorescence divided by the change in time (i.e. dF/dt), was measured as the linear portion of 
the fluorescence response profile and plotted versus anticoagulant concentration. Lag times were 
calculated by extrapolation of the linear portion of the progression curve to its intersection with a parallel 
line to the x-axis that goes through all points between the beginning of the experiment and the first 
recorded measurement. 
 
All graphs were plotted using SigmaPlot 8.0. Statistical analysis was carried out using SPSS 17.0 
software. Log transformations were applied to all reaction rates for data normalization. Intra-assay 
variability was determined using one-way analysis of variance (ANOVA) and a result of p<0.05 was 
considered statistically significant. If significance was observed, Tukey’s post-hoc test was performed. 
Homogeneity of variance was a requirement of statistical analysis and was assessed by the Levene’s test 
(p<0.05).  
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Results and discussion 
The optimized fluorogenic anti-FXa assay was found to be 4 nM FXa and 0.9 μM Pefafluor FXa, which 
was capable of statistically differentiating the log of the slope values (i.e. log (dF/dt)) in commercial 
human pooled plasma from 0 to 1 U mL
-1
 at intervals of 0.2 U mL
-1
. Linear regression analysis within the 
statistically sensitive range was also calculated returning a calibration curve and correlation coefficient of 
y = -0.51x + 2.17 and R
2
 > 0.98, respectively. Sum of squares resulted in a value of 0.05. 
In the present study, a further three commercially available FXa serine endopeptidases were examined in 
the same fluorogenic anti-Xa assay and compared in terms of assay dynamic ranges, lag times, CV and R
2
 
values, sum of squares as well as their sensitivity to UFH within the therapeutic range of 0-1.2 U mL
-1
. 
Three out of the four FXa proteins were of human origin while the remaining one was bovine.  
As can be seen in all insets from Fig. 1 to Fig. 3, all reaction progress curves are similar to that described 
by Harris et al. [3] for the assay employing Hyphen Biomed FXa. As UFH concentration increased, lag 
times were extended and reaction rates were reduced. In the case of the FXa from Sigma-Aldrich (Fig. 1, 
inset), the reaction curves reached a plateau at approximately 25,000-28,000 arbitrary fluorescent units 
(F.U.) at all anticoagulant concentrations except for 1 and 1.2 U mL
-1
 which did not level off.  This 
increment in signal indicates an increase in fluorescence intensity of ca. 17,000 F.U. Lag time values 
increased with increasing UFH concentration from 70 s to 1790 s from 0.4 to 1.2 U mL
-1
, respectively. A 
lag time was not observed when working at low UFH concentrations (i.e. 0-0.2 U mL
-1
). Table 2 
summarizes lag time values at all concentrations for all FXa reagents studied.  
 
(Fig. 1) and (Table 2) 
 
Intra-assay variability was calculated by means of statistical analysis of the log mean slope values 
obtained at all UFH concentrations.  Statistical analysis of the data showed sensitivity of the assay up to 
1.2 U mL
-1
 UFH (p<0.05). Standard deviations of triplicate measurements were within acceptable range 
as shown by CVs of no greater than 7 %, indicating good reproducibility. A linear regression was found 
between the log(dF/dt) and UFH concentration in the assay sensitive range 0-1.2 U mL
-1
 (Fig. 1). The 
linear calibration curve equation was y = -1.01x + 1.78 with R
2
 = 0.99.  Sum of squares was found to be 
0.99. 
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The reaction progress curve of the fluorogenic anti-FXa assay when using FXa from Enzyme Research 
Laboratories Ltd. (Fig. 2, inset) reached a plateau at approximately 27,000 F.U. independent of 
anticoagulant concentration, which indicates an increase in fluorescence intensity of ca. 16,000 F.U. The 
lag time values observed on this occasion varied from 430 s up to 1570 s when working at UFH 
concentrations of 0.4–1.2 U mL-1 UFH (Table 2). No lag time was observed from 0-0.2 U mL-1. These 
values indicate a slightly slower fluorogenic anti-FXa assay when compared with the assay in the 
presence of FXa from Sigma-Aldrich.  
 
(Fig. 2) 
 
The statistically sensitive range was established as 0-1.2 U mL
-1
 UFH (p<0.05), similar to the assay using 
FXa from Sigma-Aldrich. Reproducibility was found to be ≤ 2 %CV indicating good assay precision. The 
linear calibration curve equation taking into consideration all points in the statistically sensitive range of 
the log/lin plot (Fig. 2) was y = -0.64x + 1.79 and the R
2 
value observed was 0.95. It should be noted that 
linearity in the early part of the semi-logarithmic dose-response curve (i.e. from 0-0.2 U mL
-1
) is poor 
when compared with the rest of the concentration values as seen visually. In order to mathematically 
confirm this, sum of squares was performed in the presence and absence of the value at 0 U mL
-1
.  When 
considering the log(dF/dt) value at 0 U ml
-1
, sum of squares resulted in a value of 0.20 while in its 
absence it decreased down to 0.11.  These results indicated that the linear behaviour of the calibration 
curve could be largely improved when the log(dF/dt) value was not taken into consideration at 0 U mL
-1
.  
Fig. 3 (inset) shows the fluorescence response profile of the fluorogenic anti-FXa assay using FXa from 
Haematologic Technologies Inc. The fluorescence kinetic profile reached a plateau at approximately 
27,000 F.U. at all UFH concentrations except at 1 and 1.2 U mL
-1
; this corresponds to an increase in 
fluorescence intensity of ca. 11,500 F.U. The enzymatic reaction did not show any lag time between 0-0.2 
U mL
-1
 UFH. Nevertheless, the lag time values observed from 0.6-1.2 U mL
-1
 UFH were the largest of the 
four FXa proteins varying from 860 s up to at least 3600 s. Taking into account Table 2, overall values 
indicate an increase in the following order: Hyphen Biomed < Sigma-Aldrich ~ Enzyme Research 
Laboratories Ltd. < Haematologic Technologies Inc.  
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(Fig. 3) 
 
As can be seen in Fig. 3, the slope value at 1.2 U mL
-1
 could not be determined as the reaction did not 
take place during the time-frame of the experiment. Tukey’s post-hoc test proved that the assay sensitivity 
ranged from 0-1 U mL
-1
 UFH (p<0.05) but no significant differences were observed between 0-0.2 and 
0.6-0.8 U mL
-1
. CV values at all concentrations were <3.5%.  The calibration curve of the assay sensitive 
range (Fig. 3) was fitted to the linear regression equation y = -1.13x + 1.97 with an R
2
 of 0.96. Sum of 
squares resulted in a value of 0.47. 
The four fluorogenic anti-FXa assays were compared considering different factors such as sensitivity to 
UFH, dynamic range, lag times, CV and R
2
 values as well as the sum of squares. Table 3 summarises all 
parameters taken into account when analysing similarities and differences in the anti-FXa fluorogenic 
assay performance depending on the FXa employed. 
 
(Table 3) 
Comparison of the four fluorogenic anti-FXa assays in terms of their intra-assay variability to UFH 
resulted in assays capable of measurement up to 1 U mL
-1
 (p<0.05) when human FXa was sourced from 
Hyphen Biomed and Haematologic Technologies Inc. FXa from Hyphen Biomed is available in 
lyophilized state in the presence of a mixture of stabilizers, whereas FXa from Haematologic 
Technologies Inc. is in aqueous form using 50% (v/v) glycerol/water stabilizer solution. FXa obtained 
from Sigma-Aldrich or Enzyme Research Laboratories Ltd. increased the UFH sensitive range to 1.2 U 
mL
-1
 (p<0.05). The FXa from Sigma-Aldrich is bovine in nature and comes in liquid state (50/30% 
glycerol/water) whereas the origin of the FXa from Enzyme Research Laboratories Ltd. is human and it 
exists as a lyophilized solid without stabilizers. It has been reported by Lai and Topp [12] that proteins in 
solid form are generally more stable than the respective aqueous formulations. On this occasion, the 
physical state of the formulation seems not to have a major effect on assay performance as assay dynamic 
ranges were independent of this property.  
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Another parameter to consider is protein source. All FXa proteins were human in origin except for the 
FXa obtained from Sigma-Aldrich which was bovine. As indicated by the manufacturers, all FXa 
reagents were derived from homogeneous/highly purified FX activated by Russells’ Viper Venom 
(RVV). Thus, it could be speculated that significant differences can be found in the peptide sequences of 
the proteins depending on the source, which may account for differing performances. For instance, 
Edwards et al. [13] compared human and rabbit coagulation factor X in terms of different parameters, and 
concluded that significant structural and physiological differences exist between both FXs. The activation 
of FX to FXa by RVV was found to be 30% slower for the rabbit protein than for the human FX. 
Moreover, lower chromogenic substrate cleavage rates were observed for the rabbit FX than those by 
human protein. However, Chen et al [14] characterised and compared both porcine and human FVII and 
FX finding similarities in nucleotide, amino acid sequences and three-dimensional structure. Conversely, 
the activity of porcine FX was 1.49-fold of average human FX activity. Similar to this were other findings 
in the literature, which indicated that the m value for RVV activation of human FX was 25-fold lower 
than that for bovine FX [15, 16].  
Based on these previous observations, it can be suggested that depending on the FXa’s source different 
FXa’s activities and affinities for other compounds may indicate possible variations at FXa’s active and 
binding sites. For example, the divalent metal ion relationship with human or bovine FX was studied and 
results showed that Mn
2+
 could be substituted for Ca
2+
 when bovine FXa was employed. Contrary to this, 
human FXa protein could not be replaced with Mg
2+
 or Mn
2+
 [16, 17].  
Assay sensitivity is given by the slope values of the linear semi-logarithmic dose-response calibration 
curves. The larger its negative value the more sensitive the assay results. As seen in Table 3, FXa from 
both bovine Sigma-Aldrich and human Haematologic Technologies Inc. showed approximately two-fold 
higher sensitivity to UFH than the other two human lyophilised FXa proteins.  
 
It should be noted that all FXa reagents investigated exhibited linear calibration curves with R
2
 values of 
0.95, 0.95, 0.96 and 0.99, the last two values correspond to FXa from Haematologic Technologies Inc. 
and Sigma-Aldrich, respectively. Another criterion for whether a fit is reasonable it is the sum of squares. 
Values were calculated for all reagents increasing in the following order: Hyphen Biomed (0.05) < 
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Enzyme Research Laboratories Ltd. (0.20) < Haematologic Technologies Inc. (0.47) < Sigma-Aldrich 
(0.99). The smaller the sum of squares the better the fit but also, something to consider is that the sum of 
squares will grow with the size of the data collection. Therefore, considering our results and data set, FXa 
from Hyphen Biomed seems to fit better the data to a linear calibration curve than FXa from 
Haematologic Technologies Inc. In the case of FXa from Enzyme Research Laboratories Ltd. and Sigma-
Aldrich, the former showed lower sum of squares than the latter although linearity in the early part of the 
semi-logarithmic dose-response curve was poor as previously indicated. Hence, FXa bovine in origin 
seems to offer more assay precision. 
Moreover, CVs were <5 % for FXa from Enzyme Research Laboratories Ltd. and Haematologic 
Technologies Inc. while <7 % for the other two human proteins. Another parameter to take into account 
for the different behaviour of the four FXa reagents is purity. Haematologic Technologies Inc. as well as 
Enzyme Research Laboratories Ltd. reported a purity value > 95% tested by SDS-PAGE analysis, but 
accurate information on the other commercial FXa proteins was unavailable. It is well known that protein 
purity influences protein activity [18,19]. Therefore, reproducibility and the affinity properties of the 
different commercial FXa reagents towards the fluorogenic substrate can also be related to their purity 
values.  
To summarise, lyophilised human FXa from Hyphen Biomed returned the shortest lag time values with a 
statistically sensitive UFH range up to 1 U mL
-1
, CV and R
2
 values of <7 % and 0.95, respectively. On 
the other hand, lyophilised human FXa from Haematologic Technologies Inc. showed the largest lag time 
values and was one of the most sensitive assays up to 1 U mL
-1
. CV and R
2
 values were <3.5 % and 0.96, 
respectively. Both bovine and human FXa proteins from Sigma-Aldrich and Enzyme Research 
Laboratories Ltd. demonstrated similar behaviour in terms of lag time values and a more extended UFH 
sensitive range from 0-1.2 U mL
-1
. Nevertheless, liquid bovine FXa from Sigma-Aldrich resulted in the 
most sensitive fluorogenic anti-FXa assay, and a more precise linear calibration curve with an R
2
 value of 
0.99 considering all data points.  
From these results, it can be concluded that after taking into consideration all different factors such as 
assay sensitivity to UFH, dynamic range, lag times, sum of squares as well as CV and R
2
 values, the best 
performing FXa reagent in the fluorogenic anti-FXa assay was bovine in nature and in liquid form 
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(Sigma-Aldrich), followed by lyophilised human FXa in the absence of stabilisers (Enzyme Research 
Laboratories Ltd). 
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Legends for illustrations 
Fig. 1 Semi-logarithmic dose-response calibration curve of UFH in pooled plasma in the fluorogenic anti-
FXa assay with FXa sourced from Sigma-Aldrich. The linear calibration curve obtained was y = -1.01x + 
1.78, R
2 
= 0.99. Inset: Fluorescence intensity vs. time for the fluorogenic assay run within the range 0–1.2 
U mL
-1
 UFH in human pooled commercial plasma. UFH concentration increases from left to right (n=3) 
Fig. 2 Semi-logarithmic dose-response calibration curve of UFH in pooled plasma in the fluorogenic anti-
FXa assay with FXa sourced from Enzyme Research Laboratories Ltd. The linear calibration curve 
obtained, when considering all points, was y = -0.64x + 1.79, R
2 
= 0.95. Inset: Fluorescence intensity vs. 
time for the fluorogenic assay run within the range 0–1.2 U mL-1 UFH in human pooled commercial 
plasma. UFH concentration increases from left to right (n=3) 
Fig. 3 Semi-logarithmic dose-response calibration curve of UFH in pooled plasma in the fluorogenic anti-
FXa assay with FXa sourced from Haematologic Technologies Inc. The linear calibration curve obtained 
was y = -1.13x + 1.97, R
2 
= 0.96. Inset: Fluorescence intensity vs. time for the fluorogenic assay run 
within the range 0–1.2 U mL-1 UFH in human pooled commercial plasma. UFH concentration increases 
from left to right (n=3) 
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Table 1 Properties of four commercial FXa reagents 
Manufacturer
a
 Source Physical state Stabilizers Purity 
Hyphen Biomed Human Lyophilized 
Glycine, Prionex, PEG 
6000, sodium chloride 
- 
Enzyme Research 
Laboratories Ltd. 
Human Lyophilized none 
> 95% 
Haematologic 
Technologies Inc. 
Human Liquid 50% (v/v) glycerol/H2O 
> 95% 
Sigma-Aldrich Bovine Liquid 50/30% (v/v) glycerol/H2O - 
a
 All FXa reagents were reported to have Mw of ~ 46 KDa 
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Table 2 Lag time values and standard deviation of the fluorogenic anti-FXa assay in the presence of 
four different commercial FXa proteins within the range of 0–1.2 U mL-1 UFH 
[UFH] (U mL
-1
) Lag time values
b
 (s) 
 
Hyphen 
Biomed 
Sigma-Aldrich 
Enzyme Research 
Laboratories Ltd. 
Haematologic 
Technologies Inc. 
0 0 0 0 0 
0.2 160 ± 10 0 0 0 
0.4 225 ± 10 70 ± 25 430 ± 25 70 ± 10 
0.6 390 ± 20 200 ± 60 700 ± 60 860 ± 100 
0.8 430 ± 20 580 ± 0 860 ± 20 1140 ± 105 
1 660 ± 30 1320 ± 110 1230 ± 0 2050 ± 195 
1.2 850 ± 10 1790 ± 30 1570 ± 100 3600 ± 0 
b 
Average of triplicate measurements (n=3) 
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Table 3 Summary table of the fluorogenic anti-FXa assay in the presence of four different commercial 
FXa proteins 
Parameters 
Hyphen 
Biomed 
Sigma-Aldrich 
Enzyme Research 
Laboratories Ltd. 
Haematologic 
Technologies Inc. 
Sensitivity 
(log(dF/dt) mL U
-1
) 
-0.5 -1 -0.6  -1.1 
Dynamic range (U mL
-1
) 0-1 0–1.2 0–1.2 0-1 
CV (%) <7 <7 ≤2 <3.5 
R
2
 0.95 0.99 0.95 0.96 
Sum of squares 0.05 0.99 0.20 0.47 
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